These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 26681820)

  • 41. [Chemohyperthermia using MMC in non-muscle-invasive bladder cancer: Current status and future perspectives.].
    Coenen JJMJH; van Valenberg FJP; Arends TJH; Witjes JA
    Arch Esp Urol; 2018 May; 71(4):400-408. PubMed ID: 29745929
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993).
    Oosterlinck W; Kirkali Z; Sylvester R; da Silva FC; Busch C; Algaba F; Collette S; Bono A
    Eur Urol; 2011 Mar; 59(3):438-46. PubMed ID: 21156335
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epirubicin: a review of its intravesical use in superficial bladder cancer.
    Onrust SV; Wiseman LR; Goa KL
    Drugs Aging; 1999 Oct; 15(4):307-33. PubMed ID: 10582777
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.
    Nepple KG; Lightfoot AJ; Rosevear HM; O'Donnell MA; Lamm DL;
    J Urol; 2010 Nov; 184(5):1915-9. PubMed ID: 20846688
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Single instillation of mitomycin C plus bacillus Calmette-Guérin (BCG) versus BCG alone in high grade non-muscle invasive bladder cancer.
    Weiss BE; Pietzak EJ; Wein AJ; Malkowicz SB; Guzzo TJ
    Can J Urol; 2015 Aug; 22(4):7876-81. PubMed ID: 26267025
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?
    Park J; Song C; Shin E; Hong JH; Kim CS; Ahn H
    Urol Oncol; 2013 Aug; 31(6):849-56. PubMed ID: 21782482
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guérin immunotherapy.
    Lee JY; Diaz RR; Cho KS; Lim MS; Chung JS; Kim WT; Ham WS; Choi YD
    J Urol; 2013 Oct; 190(4):1192-9. PubMed ID: 23648222
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy.
    Barlow L; McKiernan J; Sawczuk I; Benson M
    BJU Int; 2009 Oct; 104(8):1098-102. PubMed ID: 19389012
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Intravesical therapy with mitomycin through electromotive drug administration].
    Verri C; Liberati E; Celestino F; De Carlo F; Torelli F; Di Stasi SM
    Urologia; 2013; 80(2):105-11. PubMed ID: 23852927
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mitomycin C for the treatment of bladder cancer.
    Volpe A; Racioppi M; D'Agostino D; Cappa E; Filianoti A; Bassi PF
    Minerva Urol Nefrol; 2010 Jun; 62(2):133-44. PubMed ID: 20562793
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
    Järvinen R; Kaasinen E; Sankila A; Rintala E;
    Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tumor multiplicity is an independent prognostic factor of non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin immunotherapy.
    Ajili F; Manai M; Darouiche A; Chebil M; Boubaker S
    Ultrastruct Pathol; 2012 Oct; 36(5):320-4. PubMed ID: 23025650
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer.
    Witjes JA; Caris CT; Mungan NA; Debruyne FM; Witjes WP
    J Urol; 1998 Nov; 160(5):1668-71; discussion 1671-2. PubMed ID: 9783928
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial.
    Solsona E; Madero R; Chantada V; Fernandez JM; Zabala JA; Portillo JA; Alonso JM; Astobieta A; Unda M; Martinez-Piñeiro L; Rabadan M; Ojea A; Rodriguez-Molina J; Beardo P; Muntañola P; Gomez M; Montesinos M; Martinez Piñeiro JA;
    Eur Urol; 2015 Mar; 67(3):508-16. PubMed ID: 25301758
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Management of Ta, T1, and in situ bladder carcinoma: what is new?].
    Irani J
    Prog Urol; 2008 May; 18 Suppl 5():S94-8. PubMed ID: 18585634
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bladder cancer in Spain 2011: population based study.
    Miñana B; Cózar JM; Palou J; Unda Urzaiz M; Medina-Lopez RA; Subirá Ríos J; de la Rosa-Kehrmann F; Chantada-Abal V; Lozano F; Ribal MJ; Rodríguez Fernández E; Castiñeiras Fernández J; Concepción Masip T; Requena-Tapia MJ; Moreno-Sierra J; Hevia M; Gómez Rodríguez A; Martínez-Ballesteros C; Ramos M; Amón Sesmero JH; Pizá Reus P; Bohorquez Barrientos A; Rioja Sanz C; Gomez-Pascual JA; Hidalgo Zabala E; Parra Escobar JL; Serrano O
    J Urol; 2014 Feb; 191(2):323-8. PubMed ID: 23994371
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study.
    Gudjónsson S; Adell L; Merdasa F; Olsson R; Larsson B; Davidsson T; Richthoff J; Hagberg G; Grabe M; Bendahl PO; Månsson W; Liedberg F
    Eur Urol; 2009 Apr; 55(4):773-80. PubMed ID: 19153001
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer.
    Chen CH; Yang HJ; Shun CT; Huang CY; Huang KH; Yu HJ; Pu YS
    Urol Oncol; 2012; 30(4):421-7. PubMed ID: 20870427
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
    Martínez-Piñeiro L; Portillo JA; Fernández JM; Zabala JA; Cadierno I; Moyano JL; Solsona E; Unda M; Beardo P; Rodríguez-Molina J; Chantada V; Palou J; Muntañola P; Alonso Dorrego JM; Pérez-Garcia FJ; Silva JM; Chesa N; Montesinos M; Ojea A; Madero R; Martínez-Piñeiro JA
    Eur Urol; 2015 Aug; 68(2):256-62. PubMed ID: 25794457
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The value of transurethral bladder biopsy after intravesical bacillus Calmette-Guérin instillation therapy for nonmuscle invasive bladder cancer: a retrospective, single center study and cumulative analysis of the literature.
    Swietek N; Waldert M; Rom M; Schatzl G; Wiener HG; Susani M; Klatte T
    J Urol; 2012 Sep; 188(3):748-53. PubMed ID: 22819422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.